BridgeBio Pharma, Inc. financial data

Symbol
BBIO on Nasdaq
Industry
Pharmaceutical Preparations
Location
3160 Porter Dr., Suite 250, Palo Alto, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
BridgeBio Pharma LLC (to 5/16/2019)
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 415 % -15%
Debt-to-equity -159 % -8.65%
Operating Margin -250 % +95.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 189M shares +8.64%
Common Stock, Shares, Outstanding 189M shares +8.53%
Entity Public Float 2.08B USD +112%
Common Stock, Value, Issued 195K USD +8.33%
Weighted Average Number of Shares Outstanding, Basic 189M shares +15.4%
Weighted Average Number of Shares Outstanding, Diluted 189M shares +15.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 218M USD +2210%
Cost of Revenue 2.39M USD 0%
Research and Development Expense 506M USD +21.6%
Costs and Expenses 762M USD +34%
Operating Income (Loss) -544M USD +2.65%
Nonoperating Income (Expense) 98.1M USD
Income Tax Expense (Benefit) 0 USD
Earnings Per Share, Basic -2.42 USD/shares +37.8%
Earnings Per Share, Diluted -2.42 USD/shares +37.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 266M USD -47.3%
Marketable Securities, Current 39.8M USD +29%
Assets, Current 445M USD -24.3%
Property, Plant and Equipment, Net 8.7M USD -29.9%
Operating Lease, Right-of-Use Asset 6.44M USD -31%
Intangible Assets, Net (Excluding Goodwill) 24.5M USD -8.89%
Other Assets, Noncurrent 20.3M USD +8.65%
Assets 665M USD +1.52%
Accounts Payable, Current 13.4M USD +199%
Employee-related Liabilities, Current 43.5M USD +29.1%
Liabilities, Current 139M USD +31.3%
Operating Lease, Liability, Noncurrent 5.83M USD -40.6%
Other Liabilities, Noncurrent 377K USD -96.8%
Liabilities 1.88B USD +1.87%
Accumulated Other Comprehensive Income (Loss), Net of Tax 5K USD -85.3%
Retained Earnings (Accumulated Deficit) -2.83B USD -18.3%
Stockholders' Equity Attributable to Parent -1.23B USD -1.85%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -1.22B USD -2%
Liabilities and Equity 665M USD +1.52%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -220M USD -52.1%
Net Cash Provided by (Used in) Financing Activities 280M USD +86.1%
Net Cash Provided by (Used in) Investing Activities 22.8M USD +85%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 195M shares +8.24%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 82.8M USD +354%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 408M USD -22.2%
Interest Paid, Excluding Capitalized Interest, Operating Activities 35.3M USD +60.1%
Deferred Tax Assets, Valuation Allowance 672M USD +25.9%
Deferred Tax Assets, Gross 679M USD +25.9%
Operating Lease, Liability 10.4M USD -25.2%
Payments to Acquire Property, Plant, and Equipment 695K USD +5692%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -439M USD +28.3%
Lessee, Operating Lease, Liability, to be Paid 11.6M USD -27.2%
Operating Lease, Liability, Current 4.6M USD +11.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.28M USD -42.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 5.11M USD +3.82%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.14M USD -41.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 464K USD -75.2%
Deferred Tax Assets, Operating Loss Carryforwards 359M USD +10.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 25M shares 0%
Unrecognized Tax Benefits 30.9M USD +14.2%
Lessee, Operating Lease, Liability, to be Paid, Year Four 464K USD -45.3%
Operating Lease, Payments 1.6M USD +27.6%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 2.4M USD +14.3%
Depreciation, Depletion and Amortization 1.6M USD -2.27%
Deferred Tax Assets, Net of Valuation Allowance 6.47M USD +25.5%
Share-based Payment Arrangement, Expense 115M USD +14%
Interest Expense 87M USD +8.01%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%